ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU.
The applications were submitted for a single-tablet, including two-drug regimen of dolutegravir and rilpivirine for maintenance treatment of HIV-1 infection.
If approved, the therapy will be the first two-drug regimen for the maintenance treatment of HIV-1 infection offering patients who are virally suppressed the option to switch to a regimen which... Readmore
European Union regulators have cleared a spinal muscular atrophy therapy, with the hope that the new treatment can have a major impact on treating the condition.
Spinal muscular atrophy is a rare and often fatal genetic disease that impacts upon the muscular strength and movements.
In response to this debilitating condition, the European commission has approved Biogen's Spinraza (nusinersen) as a first line treatment of 5q spinal muscular atrophy.
This form of the disease accounts for approximately... Readmore
The Guardian newspaper has reported that beta-blockers may be over prescribed.
Picking up on a study which examined the commonly used medicine, the publication noted that “many patients given beta-blockers after a heart attack may not benefit from being on the drugs”.
Beta-blockers are used to regulate the heart by making it beat more slowly and with less force.
They are most frequently prescribed for those to be facing the risk of heart failure.
Yet the new study involving English... Readmore
New research funded by Pfizer suggests that patients effectively experience a placebo effect when taking statins.
The study found that those who take statins and are told that they are doing so experience more side-effects than those who are unaware.
Researchers at Imperial College London conducted the study, which has been published in The Lancet journal.
Clinical studies have previously demonstrated that side-effects are at similar levels in patients either taking a statin or placebo.
Cost regulators have made what seems to be a significant U-turn over Takeda’s Adcetris, with the likelihood that it will be possible for Hodgkin lymphoma to gain routines NHS access to the drug.
Adcetris (brentuximab vedotin) has already been cleared in Europe to treat CD30-positive Hodgkin’s.
But Nice had rejected the drug due to cost-effectiveness concerns.
The healthcare body also cited what it considered to be uncertainties in evidence related to the drug.
Yet Nice has now reversed... Readmore
National Institute for Health and Care Excellence experts have supported the use of Janssen’s biologic Stelara.
The substance is utilised in order to treat adult patients with Crohn’s disease, with Stelara able to deal with some of the more severe cases.
A Final Appraisal Determination has already been issued recommending the drug in line with its licensed indication.
Stelara will be used when patients fail to respond to conventional therapy or an anti-TNF-alpha therapy.
Crohn's is known... Readmore
Representatives of the pharmaceutical industry have collectively suggested that many firms could withdraw from Britain and delay major drug launches unless the NHS receives a funding boost.
The manifesto of the Association of the British Pharmaceutical Industry (ABPI) suggests that health spending should be boosted to 11% of GDP from 9.9%.
This would amount to approximately £20 billion annually.
Lisa Anson, the new president of the ABPI and country president of AstraZeneca, suggested that... Readmore
Wales is to receive the game-changing Prep HIV drug, as part of a three-year trial.
This is despite the fact that the All Wales Medicines Strategy Group (AWMSG) has previously advised the Welsh government to oppose the funding of Prep due to its lack of cost-effectiveness.
AWMSG had stated previously that there were "several uncertainties and limitations" in the economic model provided by the manufacturer of the drug.
But Health Secretary Vaughan Gething has announced that during the research... Readmore
New clinical data indicates that a major form of medication has a massive impact on a prominent virus.
AbbVie’s late-stage information demonstrates that the ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir has achieved high cure rates across the majority of patients infected with the virus.
Glecaprevir/pibrentasvir is a once-daily regimen that combines two distinct antiviral agents.
Both the NS3/4A protease inhibitor glecaprevir (300mg) and NS5A inhibitor pibrentasvir (120mg)... Readmore
The National Institute for Health and Care Excellence (NICE) has backed the utilisation of Novartis’ Cosentyx (secukinumab) in adults with active and progressive psoriatic arthritis.
Progressive psoriatic arthritis is an inflammatory disease that affects joints and connective-tissue, impacting over 117,000 people in Britain.
It can strike at any point during a person's lifetime, but the most affected the group are those aged between 40 and 50.
The watchdog is already recommending the use of Cosentyx... Readmore
The pharmaceutical company Allergan has announced a major collaboration with Novartis.
This new arrangement between the pharma giants will see them test a new combination therapy approach for non-alcoholic steatohepatitis.
Non-alcoholic steatohepatitis is a progressive form of non-alcoholic fatty liver disease that is considered to be the fastest growing cause of liver cancer and liver transplant in the United States.
In order to achieve this, Allergan is expanding its research and development... Readmore
Onzima Ventures has announced the conditional acquisition of the remaining 51% of the issued shares of N4 Pharma Limited, effectively taking over the firm.
Consideration for the acquisition will be satisfied by the issue of 4,510,800 New Ordinary Shares and 4,591,400 Deferred Consideration Shares.
The Company has also conditionally raised £1.5 million (gross) by way of a placing of 21,428,571 New Ordinary Shares at 7p per share .
This will be utilised in order to fund development of additional... Readmore